Your treatment for depression could change lives
Let’s prove it, together
Generate the evidence you need faster with Clario
Assessing psychiatric drugs is complex. It requires a comprehensive approach to track disease progression, monitor safety, and understand the impact on quality of life. This is made possible by integrating clinical outcome assessments, imaging data, and cardiac safety endpoints.
Learn how Clario can help by watching our on-demand webinar.
Your Major Depressive Disorder (MDD) drug is unique.
But,
Our global scientific and medical teams can help you answer these critical questions with confidence.
Achieve fast, accurate results with expertise in MDD clinical trials
Gain the confidence to make informed, critical decisions at every phase with Clario’s reliable, accurate and proven solutions. With over 50 years of clinical trial experience and support for 400+ MDD trials worldwide, we understand your trial’s unique challenges.
Streamline your drug development journey and unlock new insights. Discover how our comprehensive approach can enhance your clinical trial. Learn more by watching our webinar recording.
Overcome the key challenges in MDD clinical trials through Clario’s proven approach to:
High prevalence and under diagnosis
MDD and mood disorders affect millions worldwide, yet many cases remain undiagnosed due to stigma or limited awareness. Our expert teams help you design patient-centric, accessible studies to help reflect real-world populations, ensuring broader diagnostic reach.
Complex endpoints and variability
Traditional clinician-reported outcomes such as MADRS, HAM-D, and YMRS can suffer from variability across sites and investigators. Our eCOA (electronic Clinical Outcome Assessments) solutions and robust training programs help streamline accurate data capture, digitizing these assessments and improving accuracy and consistency across study sites.
Managing safety
Traditional clinician-reported outcomes such as MADRS, HAM-D, and YMRS can suffer from variability across sites and investigators. Our eCOA (electronic Clinical Outcome Assessments) solutions and robust training programs help streamline accurate data capture, digitizing these assessments and improving accuracy and consistency across study sites.
Rater variability and data integrity
With our centralized rater training and rater monitoring solutions, we help you mitigate issues like rater drift and placebo response, reducing noise and improving quality of your trial data, boosting the accuracy of your results.
Placebo response
Understanding treatment efficacy through brain function
Characterization of the MDD disease state and its relationship to brain function is key to understanding a compound’s effectiveness. Clario’s advanced imaging capabilities provide insights into brain responses, offering biomarkers that demonstrate psychiatric target engagement and strengthen the value of your study.
Transforming clinical trial success
Streamline your study, control costs, and optimize your time to market with our scientific expertise, operational guidance, and transformative digital endpoint solutions.